Venture Capital

Just weeks after a blockbuster IPO, travel tech firm Navan is under investigation for misleading investors as its stock plummets and its CFO departs.

With new executive leadership, AI firm HealthLeap aims to accelerate its mission of improving patient outcomes and hospital finances nationwide.

Fullscript and ŌURA are integrating biometric data into clinical workflows, promising a new era of personalized medicine. But is healthcare ready for it?

As AI costs soar, Hammerspace gains industry validation for its dynamic data platform that maximizes GPU power while slashing cloud storage expenses.

LyfeSci's acquisition of Clinically Media aims to fix the clinical trial bottleneck by integrating patient recruitment, promising faster, more diverse studies.

Sweden secures sovereign satellite capabilities in a 9-figure deal, signaling a new era of European defense autonomy and disrupting the space industry.

Following a $25M fundraise, former WA Health Secretary Dr. Shah joins Jaan Health, signaling a new era for AI-driven chronic disease management.

With AI agents creating a new security frontier, 1Password appoints former AWS exec Nancy Wang as CTO to build the 'trust layer' for non-human identities.

Biotech veteran Kamran Tavangar, who built a multi-billion dollar company at LabCentral, returns to lead its science strategy and shape the future of innovation.

Meal delivery leader Factor is now in Target stores, signaling a major shift in the booming ready-to-eat market. What does this mean for your next grocery trip?

Unrivaled's renewed partnership with Mount Sinai isn't just a deal; it's a statement on player health, setting a new benchmark for women's pro sports.

The strategic merger creates an end-to-end system connecting employee voice to business performance, challenging the competitive HR tech landscape.

With a new name and a laser focus on its lead hemophilia A drug, Metagenomi Therapeutics signals a major shift from platform tech to clinical powerhouse.

Manas AI gains unique access to Schrödinger's physics platform, uniting top minds and tech to slash drug development timelines. Is this the future?

MediKarma is licensing autonomous AI agents to manage disease and data, aiming to become the core processor for the entire healthcare industry.

NYU Langone and tech firm Tempus are launching a new protocol using serial DNA sequencing and AI to create hyper-personalized cancer treatments.

The EdTech giant is unveiling an integrated ecosystem with new AI capabilities and a Microsoft Teams solution at five major international trade shows.

Cogent Biosciences is set for a transformative year, eyeing three FDA submissions and a launch for its lead drug, with a deep pipeline to follow.

Moderna CEO Stephane Bancel joins CFS's board, signaling a major push to commercialize fusion energy. Can his vaccine scale-up success crack the code?

Biomea Fusion launches a high-stakes 2026 plan, advancing a novel diabetes drug to restore insulin cells and an oral pill to rival obesity giants.